Back to top

Analyst Blog

Shares of United Therapeutics Corporation (UTHR - Analyst Report) surged 27.5% in the past one week after the U.S. Food and Drug Administration (FDA) approved the oral use of Remodulin (treprostinil).

The oral formulation has been approved under the brand name – Orenitram for the treatment of pulmonary arterial hypertension (PAH) patients (in WHO Group I) to improve exercise capacity. We note that Remodulin is already approved for both subcutaneous (SC) and intravenous (IV) use.

The news comes as a relief for United Therapeutics as the FDA had previously issued two complete response letters (CRLs) to the company’s new drug application (NDA) for Orenitram and a final decision was expected by Feb 16, 2014.

The first CRL was issued in Oct 2012. In Jan 2013, United Therapeutics resubmitted its NDA to address the concerns raised in FDA’s CRL. However, the company suffered a setback when the FDA issued a second CRL in Mar 2013.

At the time of issuing the first CRL, the FDA had raised questions about the clinical importance of the 6 Minute Walk Distance (6MWD) effect size shown in the FREEDOM-M study, the lack of improvement in time to clinical worsening in all three phase III studies conducted with Orenitram, and the failure to show a statistically significant effect on 6MWD in the two FREEDOM-C studies.

Thereafter, United Therapeutics conducted an end of review meeting with the FDA in early May 2013 to discuss the second CRL. At that meeting, additional analyses and contextual information about combination studies in the field were presented.

United Therapeutics resubmitted its NDA, which was accepted by the FDA in Sep 2013. Hence, the approval comes as a major relief for United Therapeutics after suffering two setbacks.

However, United Therapeutics is facing a patent challenge for Remodulin injection. Novartis’ (NVS - Analyst Report) generic unit, Sandoz, is seeking approval for its generic version of Remodulin (10 mg/mL). United Therapeutics has filed a patent infringement lawsuit against Sandoz.

United Therapeutics currently carries a Zacks Rank #3 (Hold). Better-ranked stocks include Questcor Pharmaceuticals and Jazz Pharmaceuticals (JAZZ - Analyst Report). Both carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%